The United Kingdom and the United States have agreed to a major trade agreement that will keep zero duties on British medicine products being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the NHS. This pledge ensures that tariffs on these crucial goods will be held at zero for a duration of 36 months.
This agreement is in response to recent statements to hike tariffs on patented drug products, with potential rates floated as high as 100%.
"This arrangement between the Britain reinforces the international landscape for innovative medicines and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Importance
Medicines are one of the the United Kingdom's biggest exports to the US, which is easily the primary destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to last September, the UK shipped medicines totaling £11.1bn to the US. This figure made up nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards jobs, increases funding and paves the way for the UK to establish itself as a global hub for medical research," a government official commented.
Specific British Pledges
The deal entails several notable changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to raise total health service expenditure on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments topped twenty percent.
Broader Context
This agreement takes place against a protracted dispute between the sector and the UK government over spending levels and approval rates.
The disagreement were intensified by arguments that US patients were charged a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major investments have been directed toward projects in the United States.
One official acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
